Site-dependent bone mineral density response to oral pamidronate and calcium in postmenopausal osteoporosis: A preliminary report

Clinical Rheumatology

Volumn 16, Issue 4, 1997, Pages 346-352

  Barreira, J C ^a   Messina, O D ^a,d   Maldonado Cocco, J A ^b   Roldan, E J A ^c  

^a HOSPITAL GENERAL DE AGUDOS DR COSME ARGERICH   (Argentina)

^b Instituto Argentino de Diagnostico y Tratamiento   (Argentina)

^c Gador SA   (Argentina)

^d NONE   (Argentina)

Author keywords

Bone Mineral Density; Calcium; Femoral Neck; Pamidronate; Vertebra

Indexed keywords

CALCIUM; PAMIDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; BONE MINERALIZATION; CALCIUM INTAKE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; HUMAN; MAJOR CLINICAL STUDY; OSTEOCLAST; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; VERTEBRA;

EID: 0030749987     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02242450     Document Type: Article

References (22)

1. Nagant de Deuxchaisnes C, Rombouts-Lindemans C, Huaux JP, Devogelaer JP, Malghem B, Maldague B et al. Paget's disease of bone. Brit Med J 1982; 284: 274.
2. Valkema R, Vismans FLFE, Papapoulos SE, Pauwels EKJ, Bijvoet OLM. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989; 5: 183-92.
3. Devogelaer JP, Huaux JP, Nagant de Deuxchaisnes C. Bisphosphonate therapy with APD in involutional osteoporosis with vertebral crush fractures. In: Osteoporosis. Eds.: Christiansen C, Johansen JD. Osteopress, Copenhagen 1989: 950.
4. Fromm GA, Vega E, Plantalech L, Galich AM, Mautalen CA. Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis. Osteoporosis Int 1991; 1: 129-33.
5. Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med 1993; 95 (suppl 5A): 48S-52S
6. Zanchetta JR, del Valle E, Bogado CE, Spivacow FR, Pérez Lloret A. Improvement in bone mineral content in patients with osteoporosis treated with the bisphophonate APD. In: Osteoporosis Vol 3. Eds.: Christiansen C, Overgaar K. Osteopress, Copen-hagen, 1990: 1461-3.
7. Reid IA, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994; 79: 1595-9.
8. Report of WHO study group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series 843, WHO Publications, Geneva, 1994:5-6.
9. Mazess R, Collick B, Trempe J, Barden H, Hanson J. Performance evaluation of a dual energy X-ray bone densitometer. Calcif Tissue in 1989; 44: 228-32.
10. Sinclair JD. Multiple t-tests are appropriate in science. Trends Pharmacol Sci 1988; 9: 12-13.
11. Einhorn TA. Bone strength: The bottom line. Calcif Tissue Int 1992; 51: 333-39.
12. Lufkin EG, Argueta R, Whitaker MD, Cameron AL, Wong VH, Egan KS, et al. Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 1994; 4: 320-322.
13. Israel O, Lubushizky R, Frenkel A, Losilevsky G, Bettman L, Gips S et al. Bone turnover in cortical and trabecular bone in normal women and women with osteoporosis. J Nucl Med 1994; 35:1155-58.
14. Ascenzi A, Boyde A, Portigliatti Barbos M, Carando S. Micro-biomechanics vs macro-biomechanics in cortical bone. A micro-mechanical investigation of femurs deformed by bending. J Biomechanics 1987; 20: 1045-53.
15. Bagil CM, Miller SC, Bowman BM, Blomstrom GL, France EP. Differences in cortical bone in overloaded and underloaded femurs from ovariectomized rats: comparison of bone morphometry with torsional testing. Bone 1992; 13: 35-40.
16. Danielsen CC, Mosekilde L, Svenstrup B. Cortical bone mass, composition, and mechanical properties in female rats in relation to age, long-term ovariectomy, and estrogen substitution. Calcif Tissue in 1993; 52: 26-33.
17. Avioli LV. Heterogenicity of osteoporotic syndromes and the response to calcitonin therapy. Calcif Tissue Int 1991, 49 (suppl. 2): S16-S19.
18. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MML, Thesing CW, Bijvoet OLM. Two modes of action of bis- phosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1986; 1: 27-39.
19. Sahni M, Guenther HL, Fleisch H, Collin P, Martin TJ. Bisphosphonates act on bone resorption through the mediation of osteoblast. J Clin Invest 1993; 91: 2004-11.
20. Bijvoet OLM. Pamidronate (APD) in cancer therapy: the pharmacological background. In: The management of bone metastases and hypercalcemia by osteoclast inhibition. Ed.: Rubens, R. Hogrefe and Huber, New York; 1989: 13-18.
21. Ferretti JL, Cointry G, Capozza R, Montuori E, Roldán E, Pérez Lloret, A. Biomechanical effects of the full range of useful doses of (3-amino-l-hydroxypropylidene)-1,1bisphophonate(APD)on femur diaphyses and cortical bone tissue in rats. Bone Miner 1990; 11: 111-122.
22. Ferretti JL, Delgado CJ, Capozza RF, Cointry G, Montuori E, Roldán E et al. Protective effects of disodium etidronate and pamidronate against the biomechanical repercussion of betamethasone-induced osteopenia in growing rat femurs. Bone Miner 1993; 20: 265-76.